N^α-(tert-butoxycarbonyl)-α-hydroxyglycine | 96625-24-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N^α-(tert-butoxycarbonyl)-α-hydroxyglycine
• 英文别名: rac-α-(hydroxy)-N-(tert-butyloxycarbonyl)glycine；N-t-butoxycarbonyl-2-hydroxyglycine；Boc-Gly(OH)-OH；α-(hydroxy)-N-(tert-butoxycarbonyl)glycine；N-(tert-Butoxycarbonyl)-2-hydroxyglycine；2-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid
• CAS: 96625-24-0
• 化学式: C₇H₁₃NO₅
• 分子量: 191.184
• InChiKey: IJGAMYCKTKUVDY-UHFFFAOYSA-N

物化性质

• 沸点：
  362.4±32.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N^α-(tert-butoxycarbonyl)-α-hydroxyglycine 在 N-甲基吗啉 、 三氟化硼乙醚 作用下， 以 乙醚 为溶剂， 反应 20.0h， 生成 N--Phe-Pro-Lactam
  参考文献：
  名称：

  Losse, Guenter; Strobel, Juergen, Journal fur praktische Chemie (Leipzig 1954), 1984, vol. 326, # 5, p. 765 - 778

  摘要：

  DOI：
• 作为产物：
  描述：

  氨基甲酸叔丁酯 、 乙醛酸 以 丙酮 为溶剂， 反应 4.0h， 以100%的产率得到N^α-(tert-butoxycarbonyl)-α-hydroxyglycine
  参考文献：
  名称：

  Norcystine, a New Tool for the Study of the Structure−Activity Relationship of Peptides

  摘要：

  Norcysteine ( Ncy) is an unnatural amino acid possessing an electronegative sulfur atom directly attached to the alpha-carbon atom. We describe the synthesis of Boc-D, L-Ncy( Mob)-OH, the resolution of its methyl ester, and the introduction of both D- and L-Ncy in GnRH analogues.

  DOI：

  10.1021/ol0606740

文献信息

• [EN] PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRAZINE-7-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE JAK ET SYK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011144585A1

  公开（公告）日：2011-11-24

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R, R2, and R3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式（I）的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3如本文所述定义，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。
• Synthesis of Differently Protected α-Aminoglycines and Their Peptide Derivatives
  作者：Ulrich Schmidt、Florian Stäbler、Albrecht Lieberknecht

  DOI：10.1055/s-1994-25592

  日期：——

  Compatibly protected α-aminoglycine and di- and tripeptides containing it are prepared from the corresponding α-hydroxyglycines.

  受相容保护的α-氨基甘氨酸及其含有该成分的二肽和三肽，是经由相应的α-羟基甘氨酸制备的。
• Compound
  申请人：Miller David Andrew

  公开号：US20050287202A1

  公开（公告）日：2005-12-29

  The present invention provides a process for preparing a modified lipid of the formula comprising reacting (I) a compound of the formula; and (ii) a compound of the formula wherein component (ii) is formulated as a liposome; wherein B is a lipid; wherein A is a moiety of interest (MOI) and is a hydrocarbyl group; wherein X is an optional linker group; wherein R 1 is H or a hydrocarbyl group; and wherein R 2 is a lone pair, H or a hydrocarbyl group. The moiety of interest A may be selected from a carbohydrate moiety, a polymer, a peptide, a glycoprotein, a small biomolecule (such as a folic acid derivative) and a bioconjugate linker.

  本发明提供了一种制备修改脂质的方法，其中包括反应(I)化合物的公式; 和(ii)的化合物的公式其中组分(ii)被构造为一个脂质体; 其中B是一种脂质; 其中A是一个感兴趣的基团（MOI）且是一个烃基团; 其中X是一个可选的连接基团;其中R1是H或一个烃基团; 和其中R2是一个孤对，H或一个烃基团。感兴趣的基团A可以选择自碳水化合物基团、聚合物、肽、糖蛋白、小生物分子（如叶酸衍生物）和生物共轭连接剂。
• Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents
  申请人：Kohn Harold L.

  公开号：US20110021482A1

  公开（公告）日：2011-01-27

  A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.

  本发明的第一个方面是公式I或Ia的化合物（有时也在此处称为“活性剂”或“活性化合物”）：或其药学上可接受的盐或前药。还描述了其组成物和使用方法（例如用于治疗神经系统疾病）。
• Ring Size of Somatostatin Analogues (ODT-8) Modulates Receptor Selectivity and Binding Affinity
  作者：Judit Erchegyi、Christy Rani R. Grace、Manoj Samant、Renzo Cescato、Veronique Piccand、Roland Riek、Jean Claude Reubi、Jean E. Rivier

  DOI：10.1021/jm701444y

  日期：2008.5.1

  The synthesis, biological testing, and NMR studies of several analogues of H-c[Cys(3) -Phe(6) -Phe(7) -DTrp(8)- Lys(9)-Thr(10)-Phe(11)-CYS(14)] -OH (ODT-8, a pan-somatostatin analogue, 1) have been performed to assess the effect of changing the stereochemistry and the number of atoms in the disulfide bridge on binding affinity. Cysteine at positions 3 and/or 14 (somatostatin numbering) were/was substituted with D-Cysteine, norcysteine, D-norcysteine, homocysteine, and/or D-homocysteine. The 3D structure analysis of selected partially selective, bioactive analogues (3, 18, 19, and 21) was carried out in dim ethyl sulfoxide. Interestingly and not unexpectedly, the 3D structures of these analogues comprised the pharmacophore for which the analogues had the highest binding affinities (i.e., sst(4) in all cases).